Deconstructing the molecular portraits of breast cancer

Molecular Oncology - Tập 5 Số 1 - Trang 5-23 - 2011
Aleix Prat1,2,3, Charles M. Perou1,2,3
1Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2Department of Pathology & Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Tóm tắt

Breast cancer is a heterogeneous disease in terms of histology, therapeutic response, dissemination patterns to distant sites, and patient outcomes. Global gene expression analyses using high‐throughput technologies have helped to explain much of this heterogeneity and provided important new classifications of cancer patients. In the last decade, genomic studies have established five breast cancer intrinsic subtypes (Luminal A, Luminal B, HER2‐enriched, Claudin‐low, Basal‐like) and a Normal Breast‐like group. In this review, we dissect the most recent data on this genomic classification of breast cancer with a special focus on the Claudin‐low subtype, which appears enriched for mesenchymal and stem cell features. In addition, we discuss how the combination of standard clinical‐pathological markers with the information provided by these genomic entities might help further understand the biological complexity of this disease, increase the efficacy of current and novel therapies, and ultimately improve outcomes for breast cancer patients.

Từ khóa


Tài liệu tham khảo

10.1016/S1535-6108(02)00097-1

10.1080/02841860500513235

10.1073/pnas.0530291100

10.1007/BF01961241

10.1001/jama.295.21.2492

10.1158/1078-0432.CCR-06-1109

10.1016/j.stem.2010.08.008

10.1159/000101298

10.1158/0008-5472.CAN-08-2741

10.1158/1078-0432.CCR-07-1658

10.1093/jnci/djp082

10.1016/j.ccr.2006.10.009

10.1073/pnas.0905718106

10.1056/NEJMoa040766

Deisenroth C. Thorner A.R. Enomoto T. Perou C.M. Zhang Y. Mitochondrial HEP27 is a c-Myb target gene that inhibits Mdm2 and Stabilizes p53. Mol. Cell Biol. 30 3981–93.

10.1186/gb-2003-4-9-r60

10.1038/nature07733

10.1101/gad.1061803

Dowsett M Cuzick J Wales C Forbes J Mallon L Salter J Quinn E Bugarini R Baehner F Shak S. Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. San Antonio Breast Cancer Symp. 2008:abstract 53 (2008).

Eisinger F., 1998, Mutations at BRCA1: the medullary breast carcinoma revisited, Cancer Res, 58, 1588

10.1200/JCO.2005.04.3034

10.1093/jnci/djn309

10.1158/0008-5472.CAN-05-2853

10.1093/jnci/92.7.564

10.1056/NEJMoa052933

10.1186/bcr1982

10.1093/jnci/djg050

10.1016/j.stem.2007.08.014

10.1172/JCI39397

10.1016/j.cell.2009.06.034

10.1038/nm0909-1010

10.1093/jnci/58.6.1795

10.1200/JCO.2004.00.9589

Hennessy B. Gonzalez-Angulo A. Stemke-Hale K. Gilcrease M. Krishnamurthy S. Lee J. Fridlyand J. Mills G. Characterization of a naturally occurring breast cancer subset enriched in EMT and stem cell characteristics. Cancer Res. in press.

10.1186/gb-2007-8-5-r76

10.1200/JCO.2006.05.6861

Hollestelle A., 2009, Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines, Breast Cancer Res. Treat

10.1186/bcr2108

10.1038/sj.bjc.6690196

10.1186/1471-2164-7-96

10.1200/JCO.2008.18.1024

10.3322/caac.20006

10.1200/JCO.2009.23.3734

10.1016/j.stem.2009.02.003

2006 B. Kaufman J. Mackey M. Clemens P. Bapsy A. Vaid A. Wardley S. Tjulandin M. Jahn M. Lehle A. Jones Trastuzumab Plus Anastrozole Prolongs Progression-free Survival in Postmenopausal Women with HER2-positive Hormone-dependent Metastatic Breast Cancer

10.1016/j.molonc.2007.02.004

10.1016/j.cell.2009.11.025

La Vecchia C. Bosetti C. Lucchini F. Bertuccio P. Negri E. Boyle P. Levi F. Cancer mortality in Europe 2000–2004 and an overview of trends since 1975. Ann. Oncol. in press.

10.1093/jnci/90.15.1138

10.1093/jnci/djn123

10.1200/JCO.2007.14.4147

10.1038/nm.2000

10.1200/JCO.2003.09.098

10.1056/NEJMoa063994

10.1186/1471-2164-9-239

10.1186/1755-8794-2-37

10.1016/j.cell.2008.03.027

10.1016/j.molonc.2010.06.005

10.1200/JCO.2005.04.3489

10.1007/s10549-007-9632-6

10.1038/nature03799

10.1016/j.stem.2010.07.010

10.1371/journal.pone.0002888

10.1016/j.ccr.2006.10.008

10.1158/1078-0432.CCR-04-0220

10.1158/1078-0432.CCR-10-1282

10.1200/JCO.2005.10.036

10.1200/jco.2009.27.18_suppl.3

10.1056/NEJMoa041588

10.1200/JCO.2005.04.7985

10.1056/NEJMc0801440

Parker J Prat A Cheang M Lenburg M Paik S Perou C. Breast Cancer Molecular Subtypes Predict Response to Anthracycline/taxane-based Chemotherapy. San Antonio Breast Cancer Symposium 2009a:(abstract 2019).

10.1200/JCO.2008.18.1370

10.1080/07357900701784238

10.1038/35021093

10.1056/NEJMoa052306

Pietras R., 1995, HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells, Oncogene, 10, 2435

Podo F. Buydens L.M.C. Degani H. Hilhorst R. Klipp E. Gribbestad I.S. Van Huffel S. W.M. van Laarhoven H. Luts J. Monleon D. Postma G.J Schneiderhan-Marra N. Santoro F. Wouters H. Russnes H.G. Sørlie T. Tagliabue E. Børresen-Dale A.-L. Triple-negative breast cancer: present challenges and new perspectives. Mol. Oncol. 4 209–29.

10.1038/nm0809-842

10.1186/bcr2635

10.1016/j.stem.2008.05.018

Resetkova E. Reis-Filho J. Jain R. Mehta R. Thorat M. Nakshatri H. Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat. in press.

10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N

10.1056/NEJMoa052122

10.1126/science.1171837

10.1073/pnas.0806092105

10.1158/1078-0432.CCR-04-2421

10.1200/JCO.2005.01.2898

10.1158/0008-5472.CAN-08-3343

10.1186/bcr1610

10.1016/j.ccr.2007.01.013

10.1093/jnci/djn419

10.1073/pnas.191367098

10.1093/jnci/djj052

Suspitsin E., 2009, Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier, Breast Cancer

10.1073/pnas.1004900107

10.1038/sj.onc.1210014

10.1056/NEJMoa021967

10.1038/415530a

10.1101/gad.1849509

10.1016/j.ijrobp.2005.01.008

10.1158/0008-5472.CAN-05-2553

10.1002/path.2407

Lyon Press WHO Classification of Tumors

10.1007/BF02616069

Thông tin
Thông tin xuất bản

Molecular Oncology

Tập 5 Số 1

5-23

Thông tin tác giả